Guided <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Ships Initial Order to New Chinese Partner, Secures $700K Contract
Guided Therapeutics, Inc., the developer of the LuViva Advanced Cervical Scan, has announced a new partnership with Hangzhou Dongye Medical Technology Company, Ltd. (HDMT) in China. The company recently completed its initial shipment of devices and single-use components to HDMT. This shipment is part of a larger agreement, including a separate $700,000 purchase order established earlier this year. From the June 27th shipment alone, Guided Therapeutics will recognize an additional $117,462 in sales revenue for Q2 2025. The first batch of three devices from the new order has already been manufactured and tested, prompting an expected $70,000 payment from HDMT in July 2025. HDMT, based in Hangzhou City, Zhejiang Province, is the exclusive provider of gynecology products for 42 hospitals conducting around two million cervical cancer screenings annually.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guided Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250702969336) on July 02, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.